Back
Speaker illustration

Doctor Daniel Tobias Michaeli

University Medical Centre of Mannheim, Mannheim (Germany)

I’m a medical doctor at the National Center for Tumor Diseases (NCT) Heidelberg. I received my M.D. with distinction from Heidelberg University. Simultaneously, I obtained a M.Sc. & B.Sc. in Management & Technology (major in biochemistry and finance & accounting) with high distinction from TU Munich and MIT. Further, I received a M.Sc. & Ph.D. in Economics with magna cum laude from the University of Wuppertal and the LSE. My previous work experience in consulting, venture capital, private equity, and finance focused on the biotech and healthcare industries. I (co-)authored +50 publications in leading medical journals (e.g. BMJ, JCO, JNCI, JNCCN) and conferences (e.g. ESMO, ASCO, ISPOR, ESC). My research focuses on drug development, clinical trials, and healthcare policy.

Presentations

Cost-effectiveness of icosapent ethyl for primary and secondary cardiovascular prevention in the UK

Event: ESC Congress 2022

Topic: Health Economics

Session: Costs and cost-effectiveness

Access
Thumbnail

Cost-effectiveness of cholesterol-lowering drugs for secondary cardiovascular prevention in the UK: ezetimibe, evolocumab, and alirocumab

Event: ESC Congress 2022

Topic: Drug therapy

Session: Lipids - Drug therapy 1

Access
Thumbnail

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources